Previous Close | 1.5200 |
Open | 1.4500 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 900 |
Day's Range | 1.4500 - 1.5000 |
52 Week Range | 1.4500 - 8.2500 |
Volume | |
Avg. Volume | 7,844 |
Market Cap | 8.017M |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.8700 |
Earnings Date | Nov 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for VERO
TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $17.6 million, down $3.9 million, or 18%, year-over-yearCash system revenue represented approximately 69% of total systems and subscrip
TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the commercial launch of its new multi-application platform Venus Versa Pro in the United States. Venus Versa Pro supports 10 different applicators that can be used individually or in combination to target a wide range of aesthetic conditions, including skin texture, acne vulgaris, vascular and pigmented lesions, facial wri
TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today a company-wide rebranding initiative, introducing Venus Aesthetic Intelligence (or "Venus AI") to reflect its new strategic vision for the company and an enhanced focus on emerging technologies in aesthetics. "It has been a transformational year for the company. With the first phase of our strategic turnaround behind us, we